Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.2.SummaryDifference1%
- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check63 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a phase I trial studying the combination of ibrutinib and pembrolizumab for treating advanced melanoma, while adding new identifiers and classifications related to metastatic melanoma stages.SummaryDifference52%
- Check70 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 5, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.4%
- Check78 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check114 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.